Table 2 A.
Cox Proportional Hazards Modeling on Progression-free Survival. Table 2 B. Cox Proportional Hazards Modeling on Overall Survival
| Table 2 A | HR | 95% CI | P value | |
|---|---|---|---|---|
| Observation (ref = pemetrexed) |
1.055 | 0.564 | 1.973 | 0.8658 |
| Epithelial (ref = other) |
0.780 | 0.380 | 1.599 | 0.4974 |
| First-line Cisplatin (ref = carboplatin) |
2.294 | 1.080 | 4.873 | 0.0307 |
| First-line <6 cycles (ref = 6 cycles) |
1.206 | 0.609 | 2.388 | 0.5914 |
| Gender (ref=Male) |
0.416 | 0.197 | 0.879 | 0.0217 |
| Performance status (ref = 0) |
2.441 | 1.161 | 5.132 | 0.0186 |
| Prior radiotherapy (ref=none) |
3.917 | 1.012 | 15.162 | 0.0480 |
| Platelets (unit=103/ul) | 1.002 | 1.000 | 1.005 | 0.0396 |
| Table 2 B | HR | 95% CI | P value | |
| Observation (ref = pemetrexed) |
1.619 | 0.787 | 3.332 | 0.1904 |
| Epithelial (ref = other) |
0.269 | 0.112 | 0.648 | 0.0034 |
| First-line Cisplatin (ref = carboplatin) |
0.847 | 0.356 | 2.016 | 0.7070 |
| First-line <6 cycles (ref = 6 cycles) |
1.142 | 0.546 | 2.385 | 0.7245 |
| Age at Randomization | 0.947 | 0.909 | 0.987 | 0.0090 |
| Performance status (ref = 0) |
9.411 | 3.178 | 27.868 | <.0001 |
| Chest pain (ref= no chest pain) |
0.196 | 0.062 | 0.618 | 0.0054 |
| Exposure to asbestos (ref= no exposure) |
4.689 | 1.873 | 11.742 | 0.001 |
| Duration of initial symptoms (ref= < 3 months) |
0.410 | 0.179 | 0.941 | 0.0354 |